- An interferon-free regimen of simeprevir (SMV; Olysio), daclatasvir (DCV; Daklinza), and ribavirin (RBV) achieved a 91% HCV-1b clearance rate in liver transplant (LT) recipients.
- Coadministration of cyclosporine (CsA) is not recommended.
Why this matters
- HCV clearance is associated with better graft survival.
- Open-label, multicenter, phase 2 SATURN study of 35 patients with post-LT HCV-1b recurrence, receiving a 24-wk regimen of SMV+DCV+RBV.
- 25 patients received tacrolimus (TAC) and 10 received CsA.
- Primary endpoint was sustained virologic response at 12/24 wk posttherapy (SVR12/24).
- Funding: Janssen.
- Median time from LT was 4.2 y; 63% were treatment-naïve and 77% had F1/F2 fibrosis.
- SVR12 was 91% (all subsequently achieved SVR24).
- 3 CsA-treated patients experienced virologic breakthrough, with emerging NS3/5A mutations.